Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.48 |
| ▸ | ICMT | O60725 | 9/20 | 0.44 |
| ▸ | PPARA | Q07869 | 4/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.38 |
| ▸ | BAD | Q92934 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | BCL2 | P10415 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5256680 | 0.86 | ICMT (0.61) | DUTICMTMCL1 | |
| SCHEMBL6030285 | 0.84 | DUT (0.51) | DUTPPARAMCL1BADPPARG | |
| SCHEMBL4988180 | 0.81 | DUT (0.47) | DUTPPARAMCL1BADPPARG | |
| SCHEMBL14522478 | 0.79 | ICMT (0.58) | ICMTMCL1 | |
| SCHEMBL2263579 | 0.78 | DUT (0.52) | DUTPPARAMCL1BADPPARG | |
| SCHEMBL2259836 | 0.78 | DUT (0.47) | DUTPPARAMCL1BADBCL2 | |
| SCHEMBL2263898 | 0.78 | DUT (0.52) | DUTLMNA | |
| SCHEMBL6030279 | 0.78 | DUT (0.51) | DUTPPARAMCL1BADPPARG | |
| SCHEMBL13204198 | 0.75 | CNR1 (0.43) | DUTICMT | |
| SCHEMBL20337987 | 0.73 | HTR2C (0.53) | DUTPPARAMCL1BADPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405305-B2 | Pyrrole-2, 5dione derivatives and their used as GSK-3 inhibitors | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1487822-B1 | PYRROLE-2,5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS | LILLY CO ELI (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20050288321-A1 | Kinase inhibitors | ELI LILLY AND COMPANY | 2005-12-29 | — | — | US | disclosed |
| CN-1639152-A | Pyrrole-2, 5-dione derivatives and their use as GSK-3 inhibitors | LILLY CO ELI (US) | 2005-07-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288321-A1 | Kinase inhibitors | ABL1, MAP3K20, MAP3K19 | DUT 1401/4885ICMT 4746/4885PPARA 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.